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Abstract
Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently
develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20. These
mutations may originate from small subclonal populations in the primary tumor that become dominant later on during
treatment. In order to detect these low-level DNA variations in the primary tumor or to monitor their progress in plasma, it is
important to apply reliable and sensitive mutation detection methods. Here, we combine two recently developed
methodologies, Differential Strand Separation at Critical Temperature (DISSECT), with peptide nucleic acid-locked nucleic
acid (PNA-LNA) polymerase chain reaction (PCR) for the detection of T790M EGFR mutation. DISSECT pre-enriches low-
abundance T790M EGFR mutations from target DNA prior to implementing PNA-LNA PCR, a method that can detect 1
mutant allele in a background of 100–1000 wild type alleles. The combination of DISSECT and PNA-LNA PCR enables the
detection of 1 mutant allele in a background of 10,000 wild type alleles. The combined DISSECT-PNA-LNA PCR methodology
is amenable to adaptation for the sensitive detection of additional emerging resistance mutations in cancer.
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Introduction
Mutations in the epidermal growth factor receptor (EGFR) are
found in many advanced lung cancer patients who respond
positively to EGFR tyrosine kinase inhibitors, gefitinib or erlotinib
[1,2]. However, many of these patients eventually relapse and
develop resistance to these EGFR inhibitors. The T790M mutation
on exon 20 of the EGFR receptor has been reported as one of the
driving mutations for the acquired resistance to gefitinib treatment
[3]. Approximately half of the patients that acquire resistance to
gefitinib are found to harbor the T790M EGFR mutation [3,4].
Many of the patients that do relapse often harbor pre-existing
T790M EGFR mutation at very low levels within the original
tumor population, leading to resistance after gefitinib treatment
[5].
Screening patients for low level T790M EGFR mutations prior
to administering gefitinib treatment may be useful for assessing the
possibility of disease relapse. Alternatively, monitoring of T790M
mutations in plasma during EGFR treatment may be useful for
future clinical decision making [6]. In both cases, detection of
mutated DNA is masked by an exceedingly high amount of wild
type DNA, which is a common technical problem when examining
surgical biopsies or samples obtained from bodily fluids such as
plasma or sputum [7–9]. The peptide nucleic acid-locked nucleic
acid (PNA-LNA) real time polymerase chain reaction is a rapid
and sensitive method that detects EGFR mutations in the presence
of 100- to 1000-fold wild type background [10]. This method has
recently been adapted for the detection of T790M EGFR mutation
in gefitinib-refractory disease by the use of the PNA ‘‘clamp’’ to
inhibit the amplification of wild type DNA [11,12]. However,
there is a need to improve the detection of the T790M mutation
even further than 1:1000, as the mutation may be present in a very
small population of tumor cells [13]. We recently developed a
novel method based on Differential Strand Separation at Critical
Temperature (DISSECT) to enrich for low level mutations in
DNA samples using magnetic bead-conjugated DNA probes [14].
DISSECT utilizes the differential denaturation properties of DNA
heteroduplexes and can therefore enrich mutations at any position
on the sequence, enabling mutation scanning and discovery [14].
Since the target sequence remains unmodified during DISSECT,
the resulting mutation-enriched DNA fraction can be used as a
template for any existing downstream detection method, including
PNA-LNA PCR.
Here we demonstrate the novel combination of DISSECT and
PNA-LNA PCR to identify extremely low levels of T790M EGFR
mutation. We demonstrate that a preliminary step of mutant
enrichment using DISSECT results in a major improvement of
PNA-LNA PCR detection method and increases the sensitivity of
detection to at least 1 mutant allele in a background of 10,000 wild
type alleles.
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Cell Lines and Genomic DNA isolation
Human male genomic DNA (Promega, cat. No. G1471) was
used as wild type control for dilution experiments with DNA
containing the T790M mutation. Genomic DNA from mutated
cell line H1975 (ATCC no. CRL-5908
TM) was extracted using the
DNeasy Blood and Tissue Kit according to manufacturer’s
protocol (Qiagen). DNA concentrations for both mutant and wild
type DNA were determined by using the Nanodrop 1000
spectrophotometer (Thermo Scientific).
PCR pre-amplification and High Resolution Melt Analysis
We first amplified 20 ng of both wild type male and 10% H1975
genomic DNA using conventional PCR in a 25 ml reaction in the
presence of DNA intercalating dye, 16LCGreen (Idaho Technol-
ogy).Briefly, PCRreagents were:16GoTaq Flexi Buffer (Promega),
2.5 mmol/L MgCl2, 0.2 mmol/L of each dNTP, 0.63U of GoTaq
Flexi DNA polymerase (Promega) and 0.2 mmol/L of forward (59-
GCTGGGCATCTGCCTCACCTCCACCGTGCAACT-39)a n d
reverse primer (59-GTCTTTGTGTTCCCGGACATAG-39). For-
wardprimerwas designed to replacetheA/GSNP presentinEGFR
exon 20 in order to generate a uniform template [15]. Thermal
cycling was done on the Cepheid SmartCycler
TM using the
following conditions: initial denaturation at 95uC for 2 min,
followed by 20 cycles at 95uC for 15 s, 55uC for 30 s and 72uC
for 30 s. Serial mutant dilutions (1%, 0.1%, and 0.01%) were
obtained by mixing pre-amplified wild type and 10% mutant DNA
to ensure that enough number of mutant copies were present in the
lower mutant dilution samples. Prior to further analysis, mutant
fractions were validated by PCR in the presence of 16LCGreen
followed by High Resolution Melt (HRM) analysis as reported
previously [16].
Alternatively, to apply the DISSECT-PNA-LNA PCR ap-
proach directly from mixed genomic DNA (as opposed to mixing
PCR products from mutant and WT) we used Phusion Hi-
Fidelity
TM DNA polymerase (New England Biolabs, Ipswich, MA)
for the pre-amplification from 300 ng of genomic wild type DNA
and H1975 mutant DNA (10%, 1%, 0.1%, and 0.01% mixtures).
The lowest dilution was anticipated to contain approximately 10
mutant molecules in the reaction. Pre-amplification was done in
25 ml reaction volume for a total of 20 cycles according to
manufacturer’s protocol (New England Biolabs). For this reaction,
0.3 mmol/L of the forward primer 59-TGGGCATCTGCCT-
CACCT-39 was used together with the reverse primer 59-
GTCTTTGTGTTCCCGGACATAG-39.
DISSECT protocol and probe design
Streptavidin-coated Dynabeads (Life Technologies, Grand
Island, NY) were coupled to dual-biotinylated probe sequence of
35 nt long complementary to the wild type allele of EGFR exon 20
(59-Dual-biotin-Spacer 18-CCA GGA GGC AGC CGA AGG
GCA TGA GCT GCG TGA TG-39; synthesized by Integrated
DNA Technologies Inc., Coralville, IA, USA). This probe was
then conjugated to streptavidin beads as per manufacturer’s
protocol (Invitrogen Life Technologies). These Dynabead-probes
were finally resuspended in a stock buffer containing 6X SSPE
Figure 1. Schematic of procedure. (A) Flowchart diagram of EGFR exon 20 mutant enrichment by DISSECT followed by PNA-LNA PCR. (B)
Schematic design of EGFR exon 20 primers, LNA probe, and PNA clamp during PNA-LNA PCR procedure.
doi:10.1371/journal.pone.0067782.g001
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concentration of 10 mg/mL and kept at 4uC.
About 10 mL of Dynabead-probes were incubated with a 1:50
dilution of pre-amplified DNA in a total volume of 50 mlo f
16Phusion Buffer. A ‘step-down anneal’ protocol was used to
hybridize DNA onto beads by denaturing the DNA-bead solution
at 95uC for 2 min, then annealing at 60uC for 2 min, 58uC for
2 min, 56uC for 2 min, 54uC for 1 min and 25uC for 5 min using
an Eppendorf Mastercycler EP machine (Eppendorf Inc.,
Hauppauge, NY). Two repeated cycles of EGFR mutant denatur-
ation from beads were done according to DISSECT protocol as
described previously [14]. Critical denaturation temperature for
T790M mutant EGFR DNA was achieved by heating the bead
solution at a temperature of 76uC for 2 min followed by
magnetization, and collection of supernatant enriched for mutant
EGFR ssDNA sequences. Critical temperature determination was
done as described previously [14]. 5 mL of DNA eluted from beads
following two rounds of DISSECT was amplified by PNA-LNA
PCR protocol [10,11] and analyzed by Sanger Sequencing (Eton
Bioscience, Cambridge, MA) using sequencing primer 59-40T-
GCTGGGCATCTGCCTCA-39. Prior to sequencing, PCR
products were treated with Exonuclease I (New England Biolabs)
and shrimp alkaline phosphatase (USB/Affymetrix).
Detection of T790M mutation by PNA-LNA PCR clamp
assay
The PNA-LNA clamp assay was done as reported previously
[11]. Briefly, reagent concentrations were the same as reported in
the PCR pre-amplification step, but 16LCGreen was replaced by
0.2 mmol/L of the PNA clamp (NH2-CTCATCACGCAGCTCA-
COOH), complementary to the wild type allele, and 0.2 mmol/L
of the fluorescent-labeled mutation detection probe containing a
locked nucleic acid (indicated by a plus sign), 6-FAM/ CTCAT-
CA+TGCAGCTCATG/BlackHoleQuencher-1 [11]. Cycling
conditions for PNA-LNA PCR were as following: 95uC for
2 min, followed by 70 cycles at 95uC for 15 s, and 60uC for 30 s.
Results and Discussion
Principle of DISSECT and PNA-LNA PCR
The flow diagram of the procedure presented in Figure 1A
demonstrates a method for the enrichment of low level EGFR
mutations using a combination of DISSECT protocol followed by
PNA-LNA PCR. Pre-amplification from genomic DNA using
gene-specific primers allows the generation of target DNA (i.e.
EGFR exon 20) that can subsequently be captured on to magnetic
beads coated with sequence-specific wild type probes. In this step-
down anneal protocol, double-stranded target DNA is denatured
at 95uC followed by a gradual decrease in temperature where
single-stranded DNA anneals to complementary probe sequences
immobilized on magnetic beads. These beads are then washed to
eliminate the unbound DNA and then subjected to a differential
denaturation step. For differential denaturation, the temperature is
raised to a critical temperature (Tc) of the probe sequence (i.e.
76uC) where the mutation-containing target DNA separates
preferentially from the beads, resulting in a supernatant enriched
Figure 2. Comparison of PNA-LNA sensitivity of detection for the T790M EGFR mutation. (A) Real-time PCR plot represents serially diluted
PCR product with T790M mutation (1%, 0.1% and 0.01%) into amplified product from wild type DNA, by conventional PNA-LNA PCR. (A, right)
Corresponding plot of the log concentration of T790M mutant DNA versus threshold cycle number. Graph shows mutant T790M serial dilution
following conventional PNA-LNA PCR. (B) Real-time PCR plot shows an increased level of detection when PNA-LNA is applied to a sample that has
undergone two rounds of mutant enrichment by DISSECT. (B, right) Corresponding graph shows mutant T790M serial dilution following PNA-LNA
PCR after DISSECT.
doi:10.1371/journal.pone.0067782.g002
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prior to collecting the final supernatant and applying downstream
analysis. We used the PNA-LNA PCR as a downstream analysis
method to detect T790M EGFR mutation as described previously
[11]. In Figure 1B, a schematic representation of the PNA-clamp
is shown, along with primers and TaqMan LNA probe for real
time detection of the T790M EGFR mutation. By combining the
two procedures (DISSECT plus PNA-LNA PCR) we were able to
identify mutation abundances of 0.01% as compared to PNA-LNA
PCR alone, where only 0.1% mutation abundances could be
reliably distinguished.
Sensitivity of Detection of T790M EGFR mutation
To obtain a panel of T790M EGFR mutations, we made serial
dilutions of pre-amplified PCR product from H1975 lung cancer
cell line, which contains the T790M mutation, into PCR product
from wild type human male genomic DNA. A dilution gradient
from 1% to 0.01% mutant-to-wild type DNA was generated to
evaluate the sensitivity of detection of PNA-LNA PCR. In
Figure 2A, PNA-LNA real-time PCR could reliably detect 1
mutant copy in a background of 1000 wild type copies of DNA.
The corresponding plot shows the log concentration of T790M
mutant DNA versus threshold cycle number and reveals an R-
squared value of 0.969 for mutant T790M serial dilution following
conventional PNA-LNA PCR. To improve the sensitivity of
detection, we added a preliminary step of DISSECT-based mutant
enrichment followed by PNA-LNA PCR. In Figure 2B, we show
that DISSECT improves PNA-LNA PCR detection of T790M
EGFR mutation by at least one order of magnitude and clearly
identifies an initial 0.01% mutant dilution when conventional
PNA-LNA PCR is preceded by two rounds of DISSECT. Plotting
of the log concentration of T790M mutation versus threshold cycle
number results in an R-squared value of 0.965. Since no
polymerase synthesis is employed during the mutant enrichment
step, DISSECT allows for a quantitative pre-enrichment of the
EGFR gene mutant population minimizing the introduction of
polymerase-induced errors. This method is optimal prior to PNA-
LNA PCR as it does not require enzymatic manipulation of the
starting material, resulting in an unmodified sequence for
downstream analysis protocols such as PNA-LNA PCR.
As an additional verification we applied the method to 300 ng
of genomic DNA starting material, instead of mixing PCR
products. This was done to ensure that at least one of the two
systems (PCR or genomic DNA mixtures) had rigorously
measured proportions of tumor and normal DNA. The serial
dilutions formed were from 10% to 0. 01% H1975 mutant
genomic DNA into wild type male genomic DNA. An initial pre-
amplification was performed as described in the methods using
Figure 3. T790M EGFR mutant enrichment analysis by HRM and Sanger Sequencing. (A) HRM analysis plots and Sanger Sequencing
chromatograms of serial dilutions of T790M EGFR mutations versus wild type DNA following conventional PCR. (B) The detection after mutant
enrichment by conventional PNA-LNA PCR using an initial mutant abundance of 1% and 0.1% T790M, c.2369C.T. (C) Improved detection after
mutant enrichment from two rounds of DISSECT followed by conventional PNA-LNA PCR from an initial mutant abundance of 1% and 0.01% T790M,
c.2369C.T.
doi:10.1371/journal.pone.0067782.g003
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TM DNA polymerase. The results were similar
to mixing PCR products as mentioned above, such that PNA-LNA
real-time PCR could detect down to ,0.1%, while two rounds of
DISSECT preceding PNA-LNA PCR could identify an initial
mutation abundance of 0.01% (Figure S1).
Analysis of T790M EGFR mutant enrichment by Sanger
Sequencing
To further validate the combination of DISSECT and PNA-
LNA PCR method, we analyzed PNA-LNA PCR amplicons using
HRM and Sanger Sequencing. In Figure 3A, we used pre-
amplified DNA as starting template and applied a nested
conventional PCR to all serial dilutions followed by HRM and
direct sequencing. As expected, this approach did not confer any
selectivity towards mutant sequences since HRM detected
between 1% and 10% mutation abundance, while Sanger
sequencing chromatograms were unable to identify the presence
of 10% or lower T790M mutation abundance. When PNA-LNA
PCR was implemented instead of conventional PCR, a mutant
enrichment of ,60-fold resulted from an initial input mutant
abundance of 1% T790M, c.2369C.T as shown in Figure 3B.
Sanger sequencing after conventional PNA-LNA PCR identified
an initial mutation abundance of 0.1–1%, in agreement with
Miyazawa et al [11]. When both DISSECT and PNA-LNA PCR
were combined in Figure 3C, the detection by Sanger sequencing
was improved to at least ,0.01% mutation abundance, i.e. an
improvement of one order of magnitude.
The combination method described above is an improvement
over PNA-LNA PCR approaches developed previously [17] as this
protocol is significantly shorter and it does not require a high
amount of starting DNA. Additionally, the present approach
provides a greater discrimination for the detection of the T790M
mutation compared to our previous report where two consecutive
rounds of COLD-PCR combined with TaqMan were necessary to
detect 0.05% mutant abundances [18]. We anticipate that
DISSECT-PNA-LNA PCR will prove useful in detecting low-
level mutations in tumor tissue prior to, or after administering
gefitinib treatment to NSCLC patients. Moreover, the combined
method can be used to detect other mutations, such as those
identified in KRAS via FLAG (Fluorescent Amplicon Generation)
or CO-amplification at Lower Denaturation temperature-PCR
(COLD-PCR) [18–22], or other EGFR mutations in NSCLC (ie.
L858R EGFR mutation) to help improve lung cancer diagnosis
and follow-up treatment options.
Supporting Information
Figure S1 PNA-LNA PCR sensitivity of detection of the
T790M mutation when starting from genomic DNA
using Phusion Hi-Fidelity
TM DNA polymerase. (A) Con-
ventional PNA-LNA PCR showing the detection of the T790M
mutant dilutions of 10%, 1%, 0.1% and 0.01% mutant-to-wild
type ratios versus wild type alone. (A, right) Corresponding plot of
the log concentration of T790M mutant DNA versus threshold
cycle number. (B) Real-time PCR plot showing the detection for
1%, 0.1% and 0.01% mutant-to-wild type ratios when PNA-LNA
is applied to a sample that has undergone two rounds of mutant
enrichment by DISSECT. (B, right) Corresponding graph shows
mutant T790M serial dilution following PNA-LNA PCR after
DISSECT.
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